About this test
Tests the BRCA1 and BRCA2 founder variants most common in the region. A negative result does not exclude other BRCA variants; full gene sequencing is available as an NGS project.
- Clinical area
- Molecular oncology
- Method
- Founder variant panel
- Sample
- EDTA whole blood · Extracted DNA
- Report languages
- EN · AR · RU
When to order
Breast or ovarian cancer at a young age, a strong family history, or assessing eligibility for PARP inhibitors.
Results are reported to the ordering physician and should be interpreted in clinical context.
Request this test
Offer this test to your patients.
Contract pricing and turnaround times are provided on request for laboratories and clinics.
Molecular oncology